<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Radiotherapy (RT) and concomitant/adjuvant therapy with temozolomide (Temodar) is a common treatment regimen for children and adults with <z:hpo ids='HP_0009733'>glioma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although temozolomide is generally well tolerated with temporary <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> as the primary dose-limiting toxicity, irreversible bone-marrow <z:mpath ids='MPATH_58'>aplasia</z:mpath> after treatment with temozolomide has been reported </plain></SENT>
<SENT sid="2" pm="."><plain>We report the case of an adolescent patient with a high-grade <z:hpo ids='HP_0009733'>glioma</z:hpo> who, after &gt;2 years of event-free survival, underwent successful bone marrow transplantation for treatment of temozolomide-induced severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) </plain></SENT>
</text></document>